NCT03509051View on ClinicalTrials.gov

Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

March 13, 2020

Study Completion Date

March 13, 2020

Conditions
Hematopoietic Stem Cell TransplantMeningococcal Vaccine
Interventions
BIOLOGICAL

B vaccination

One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.

Trial Locations (1)

94000

Henri-Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03509051 - Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter